CliffBio
small molecule

IRBESARTAN AND HYDROCHLOROTHIAZIDE

HYDROCHLOROTHIAZIDE; IRBESARTAN

Loss of exclusivity—loss of exclusivity
CompanyApotex →See this company's full patent-cliff portfolio

Drug detail

Brand nameIRBESARTAN AND HYDROCHLOROTHIAZIDE
Active ingredientHYDROCHLOROTHIAZIDE; IRBESARTAN
Strength12.5MG;300MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalOctober 2012
Marketing statusDISCN

More from Apotex

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.